drugset / Trial / NCT03346967

Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency

NCT03346967 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of adipose derived mesenchymal stem cells (AD-MSCs) therapy on sexual hormone deficiency in the middle-aged patients

Timeline

Start
2017-11-01
Primary completion
2020-02-28
Completion
2020-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipose-Derived Mesenchymal Stem Cells Cell therapy 1 cells/kg Intravenous

Indications

No indication recorded.